Transcription control by the ENL YEATS domain in acute leukaemia

Nature

Volumn 543, Issue 7644, 2017, Pages 270-274

  Erb, Michael A ^a   Scott, Thomas G ^a   Li, Bin E ^a,b,c   Xie, Huafeng ^a,b,c   Paulk, Joshiawa ^a   Seo, Hyuk Soo ^a   Souza, Amanda ^a   Roberts, Justin M ^a   Dastjerdi, Shiva ^a   Buckley, Dennis L ^a   Sanjana, Neville E ^d,e   Shalem, Ophir ^d,e   Nabet, Behnam ^a   Zeid, Rhamy ^a   Offei Addo, Nana K ^a   Dhe Paganon, Sirano ^a   Zhang, Feng ^d,e   Orkin, Stuart H ^a,b,c   Winter, Georg E ^a,g   Bradner, James E ^a,f,h  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; HEMAGGLUTININ; RNA POLYMERASE II; TRANSCRIPTION FACTOR HOXA9; DNA BINDING PROTEIN; ELL PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; MLLT1 PROTEIN, MOUSE; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION FACTOR;

CANCER; CELLS AND CELL COMPONENTS; GENETIC ANALYSIS; PATHOGENICITY; POLYMERASE CHAIN REACTION; PROTEIN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; DNA SEQUENCE; ENL YEATS DOMAIN; ENZYME ACTIVE SITE; GENE EXPRESSION PROFILING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEOMICS; RNA SEQUENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; ACUTE MYELOID LEUKEMIA; ANIMAL; CELL PROLIFERATION; CHEMISTRY; GENE EDITING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; GENOME; HUMAN; LEUKEMIA; METABOLISM; PATHOLOGY; TRANSCRIPTION ELONGATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CRISPR-CAS SYSTEMS; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EDITING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN DOMAINS; PROTEOLYSIS; RNA POLYMERASE II; TRANSCRIPTION ELONGATION, GENETIC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 85015176326     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21688     Document Type: Article

References (31)

1. Krivtsov, A. V., & Armstrong, S. A. MLL translocations, histone modifications, and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833 (2007
2. Slany, R. K. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 23, 1-9 (2005
3. Cai, S. F., Chen, C.-W., & Armstrong, S. A. Drugging chromatin in cancer: recent advances, and novel approaches. Mol. Cell 60, 561-570 (2015
4. Ott, C. J., et al. BET bromodomain inhibition targets both c-Myc, and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843-2852 (2012
5. Delmore, J. E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011
6. Zuber, J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011
7. Bernt, K. M., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011
8. Daigle, S. R., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017-1025 (2013
9. Daigle, S. R., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011
10. Guenther, M. G., et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22, 3403-3408 (2008
11. Krivtsov, A. V., et al. H3K79 methylation profiles define murine, and human MLL-AF4 leukemias. Cancer Cell 14, 355-368 (2008
12. Okada, Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005
13. Shalem, O., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014
14. Luo, B., et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA 105, 20380-20385 (2008
15. Levis, M., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro, and in vivo. Blood 99, 3885-3891 (2002
16. Wang, T., et al. Identification, and characterization of essential genes in the human genome. Science 350, 1096-1101 (2015
17. Li, Y., et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159, 558-571 (2014
18. Li, Y., et al. Molecular coupling of histone crotonylation, and active transcription by AF9 YEATS domain. Mol. Cell 62, 181-193 (2016
19. Andrews, F. H., et al. The Taf14 YEATS domain is a reader of histone crotonylation. Nat. Chem. Biol. 12, 396-398 (2016
20. Shanle, E. K., et al. Association of Taf14 with acetylated histone H3 directs gene transcription, and the DNA damage response. Genes Dev. 29, 1795-1800 (2015
21. Mueller, D., et al. A role for the MLL fusion partner ENL in transcriptional elongation, and chromatin modification. Blood 110, 4445-4454 (2007
22. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., & Cleary, M. L. A higher-order complex containing AF4, and ENL family proteins with P-TEFb facilitates oncogenic, and physiologic MLL-dependent transcription. Cancer Cell 17, 198-212 (2010
23. He, N., et al. Human polymerase-associated factor complex (PAFc) connects the super elongation complex (SEC) to RNA polymerase II on chromatin. Proc. Natl Acad. Sci. USA 108, E636-E645 (2011
24. Rubnitz, J. E., Morrissey, J., Savage, P. A., & Cleary, M. L. ENL, the gene fused with HRX in t(11; 19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid, and myeloid cells. Blood 84, 1747-1752 (1994
25. Zeisig, D. T., et al. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24, 5525-5532 (2005
26. Winter, G. E., et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015
27. Clackson, T., et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl Acad. Sci. USA 95, 10437-10442 (1998
28. Rathert, P., et al. Transcriptional plasticity promotes primary, and acquired resistance to BET inhibition. Nature 525, 543-547 (2015
29. Peterlin, B. M., & Price, D. H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 23, 297-305 (2006
30. Wilkinson, A. C., et al. RUNX1 is a key target in t(4; 11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Reports 3, 116-127 (2013
31. Shi, J., et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33, 661-667 (2015